---
title: "Tenet Healthcare projects 7% adjusted EBITDA growth in 2025 with focus on ambulatory expansion"
date: "2025-02-12 23:26:54"
summary: "Earnings Call Insights: Tenet Healthcare Corporation (NYSE:THC) Q4 2024 Management View CEO Saumya Sutaria highlighted 2024 performance as \"outstanding,\" driven by same-store revenue growth and disciplined operations. Full-year adjusted EBITDA reached $4 billion, a 13% increase over 2023, with a margin improvement of over 200 basis points. USPI adjusted EBITDA..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Earnings Call Insights: Tenet Healthcare Corporation (NYSE:[THC](https://seekingalpha.com/symbol/THC "Tenet Healthcare Corporation")) Q4 2024

### Management View

* CEO Saumya Sutaria highlighted 2024 performance as "outstanding," driven by same-store revenue growth and disciplined operations. Full-year adjusted EBITDA reached $4 billion, a 13% increase over 2023, with a margin improvement of over 200 basis points.
* USPI adjusted EBITDA grew 17% in 2024, fueled by a 7.8% increase in same-facility revenues and significant growth in high-acuity cases like total joint replacements, which rose 19% year-over-year.
* The hospital segment generated $2.185 billion in adjusted EBITDA in 2024, showcasing 9% growth despite the divestiture of 14 hospitals. Same-store hospital admissions increased 4.7%, with strong payer mix and acuity driving a 4.6% rise in same-store revenue per adjusted admission.
* The company completed the sale of 14 hospitals, generating $5 billion in gross proceeds and reducing leverage. Additionally, nearly 70 ambulatory surgical centers were added to the portfolio in 2024.
* CFO Sun Park noted Q4 consolidated adjusted EBITDA of $1.048 billion, representing a margin of 20.7%. Full-year free cash flow reached $1.1 billion, excluding $855 million in tax payments related to divestitures.

### Outlook

* For 2025, Tenet projects adjusted EBITDA in the range of $3.975 billion to $4.175 billion, a 7% growth rate at the midpoint on a normalized basis.
* USPI adjusted EBITDA is expected to grow approximately 8.5%, supported by 3% to 6% same-facility revenue growth, the addition of 10-12 de novo centers, and $250 million in annual M&A investments in the ambulatory space.
* Hospital segment EBITDA is forecasted to grow 5.7% at the midpoint, driven by 2% to 3% adjusted admissions growth and contributions from the newly opened Westover Hills facility.
* Free cash flow for 2025 is anticipated between $1.8 billion and $2.05 billion, with $1.05 billion to $1.25 billion after distributions to non-controlling interests.

### Financial Results

* Q4 2024 total net operating revenues were $5.1 billion, with consolidated adjusted EBITDA of $1.048 billion, marking a margin increase of 200 basis points compared to Q4 2023.
* USPI's Q4 adjusted EBITDA grew 14%, achieving a margin of 42.1% and an 8.6% rise in same-facility system-wide revenues. Meanwhile, the hospital segment reported Q4 adjusted EBITDA of $518 million, a 13% growth on a normalized basis.
* Full-year 2024 consolidated net operating revenues reached $20.7 billion, with $3.995 billion in adjusted EBITDA. Free cash flow excluding tax payments was nearly $2 billion.

### Q&A

* Pito Chickering, Deutsche Bank: Questioned cash flow guidance and leverage targets. CEO Sutaria noted the company's comfort with current leverage levels and emphasized share repurchase opportunities given valuation multiples.
* Jamie Perse, Goldman Sachs: Asked about volume trends. Sutaria stated that volume strength is expected to persist in 2025, with no major changes observed in demand patterns entering the year.
* Andrew Mok, Barclays: Queried about higher acuity's contribution to ASC revenues. Sutaria clarified that orthopedic line items, particularly joint replacements, are primary drivers of revenue growth due to their significantly higher case values.
* Ann Hynes, Mizuho: Inquired about M&A strategy in the surgery center market. Sutaria highlighted the company's disciplined approach and post-synergy focus to maintain attractive acquisition multiples.

### Sentiment Analysis

* Analysts expressed cautious optimism, focusing on cash flow deployment, volume durability, and M&A strategy. Some skepticism arose regarding potential regulatory risks and Medicaid policy changes.
* Management maintained a confident tone during prepared remarks, emphasizing operational discipline, strategic flexibility, and resilience against potential regulatory headwinds. During the Q&A, their tone remained steady and constructive.
* Compared to the previous quarter, analyst sentiment appeared slightly more forward-looking, with heightened scrutiny on guidance details, while management's tone was similarly confident and consistent.

### Quarter-over-Quarter Comparison

* Adjusted EBITDA for Q4 2024 saw a sequential increase from Q3 2024, with notable margin expansion in both the USPI and hospital segments.
* Compared to the prior quarter, management provided more detailed 2025 guidance, including growth expectations for USPI and hospital operations.
* Analysts' focus shifted from immediate financial performance to forward-looking metrics, such as 2025 volume trends and regulatory risks, reflecting evolving priorities.
* Sentiment remained consistent quarter-over-quarter, with management reiterating confidence in the company's strategic direction and financial stability.

### Risks and Concerns

* Regulatory changes in Medicaid and health insurance exchanges were noted as potential risks. Management emphasized operational discipline and business diversification to mitigate these threats.
* Analysts raised concerns about potential impacts of site neutrality rules and Medicaid administrative cuts. Sutaria highlighted the minimal Medicaid exposure within USPI and the company's ability to adapt to regulatory shifts.
* Supply cost pressures were acknowledged, linked to higher acuity strategies. Management expects these to stabilize in 2025.

### Final Takeaway

Tenet Healthcare delivered strong results in 2024, driven by disciplined operations, high-acuity growth, and strategic divestitures. The company projects continued momentum into 2025, with a focus on expanding its ambulatory footprint, maintaining robust free cash flow, and navigating potential regulatory challenges. Management's confidence in its strategic priorities and financial outlook underscores its commitment to shareholder value creation.

[Read the full Earnings Call Transcript](https://seekingalpha.com/symbol/THC/earnings/transcripts)

[seekalpha](https://seekingalpha.com/news/4407172-tenet-healthcare-projects-7-percent-adjusted-ebitda-growth-in-2025-with-focus-on-ambulatory)
